Tradestie Institutional Equity Comparison Engine

QLTI vs MEDX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MEDX Overall Edge

MEDX Captures Institutional Edge (1โ€“0 Pillars ยท 0โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Horizon Kinetics Medical ETF (MEDX) driven by superior Momentum & Technical. Fundamentally, QLTI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MEDX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, QLTI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MEDX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
QLTI N/M vs MEDX N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner MEDX
1Y +7.0% vs +18.6% ยท 52W Pos 86% vs 87%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
QLTI NYSE Arca
GMO International Quality ETF
Institutional Equity
$28.11
-0.81% 1D
Market Cap N/A
1M Return +2.85%
1Y Return +6.95%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 50.0 Fund 35.0 Flow 50.0 Mom 11.1
MEDX NASDAQ
Horizon Kinetics Medical ETF
Institutional Equity
$37.66
-0.92% 1D
Market Cap N/A
1M Return +4.61%
1Y Return +18.61%
Forward P/E N/M
Unified AI Score
42.6 / 100 HOLD
Tech 42.0 Fund 45.0 Flow 50.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QLTI +6.95% MEDX +18.61% Spread: +7.93 pp (MEDX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QLTI TTM Op. Margin: N/A MEDX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QLTI vs MEDX. Trailing 12-month operating profitability (QLTI N/A vs MEDX N/A) and valuation multiples (QLTI N/M vs MEDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QLTI (2) vs MEDX (0)
Institutional Metric QLTI MEDX Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 86% ($24โ€“$29) 87% ($32โ€“$39) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 0.81ฮฒ ยท 16% Vol 0.34ฮฒ ยท 19% Vol Lower Realized Risk QLTI
Unified Institutional Score Composite Signal 47.8 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite QLTI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QLTI vs MEDX Buy Guide
QLTI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QLTI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MEDX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MEDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QLTI nor MEDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.